Arecor Therapeutics PLC Arecor Granted Patents in India and the US (0726Q)
February 16 2023 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 0726Q
Arecor Therapeutics PLC
16 February 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING
PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL
PRODUCTS
- Patents further strengthen Group's extensive patent portfolio
protecting its proprietary diabetes portfolio and demonstrate
potential of innovative Arestat(TM) technology in development of
enhanced formulations of high value biologics
Cambridge, UK, 16 February 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the Indian
Patent Office has granted a patent (IN412485) protecting novel
formulations of the Group's proprietary insulin products, AT247 and
AT278, until 2038. In addition, the United States Patent and
Trademark Office has granted two patents ( US11534402 and
US11534403) protecting the Group's novel formulations of
high-concentration adalimumab until 2038.
Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "As
we continue to successfully apply our Arestat(TM) technology to
develop enhanced pharmaceutical products, it is crucial that we
maintain strong IP protection, both for the fundamental features of
our technology and for the final drug products. These three
recently granted patents demonstrate the continued strength of
Arecor's IP portfolio, providing further protection for our
differentiated in-house development products AT247 and AT278, as
well as within competitive IP areas such as that surrounding
adalimumab formulations. These patents further reinforce the
strength of Arecor's technology and expertise in valuable
commercial areas such as inflammatory diseases and diabetes."
The patent granted in India protects the formulations of
Arecor's clinical insulin candidates, AT247 and AT278, that have
been designed to significantly ac celerate insulin absorption post
injection across a range of insulin concentrations and thus enable
more effective management of blood glucose levels for people living
with diabetes, particularly around difficult to manage mealtimes.
The granted Indian patent is an important milestone in Arecor's
strategy to generate a strong protection through a combination of
both narrow and broad interrelated IP rights that cover the
features of these products, within key markets, adding to patents
already granted in the US, South Korea and Japan.
Adalimumab, sold by AbbVie under the brand name Humira(R), has
been a blockbuster monoclonal antibody product since its launch in
2003, with the market shifting to use the high concentration
version in the last few years. Formulating a high concentration
version of adalimumab is technically challenging and further
complicated by a complex patent landscape surrounding adalimumab
formulations. Using its Arestat (TM) technology, Arecor has
developed novel formulations enabling a high-concentration
adalimumab product (100 mg/mL or higher) with excellent stability.
The two granted US patents protect the novel formulation space
enabling these formulations and follow earlier, similar patents,
granted in Europe.
Arecor has invested in building a strong patent portfolio to
protect the Arestat(TM) technology platform and its proprietary
pipeline products. The Group's intellectual property (IP) portfolio
currently comprises 36 patent families, including >50 granted
patents in Europe, the US and in other key territories. The
recently granted patents represent an important addition to
Arecor's extensive IP portfolio.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arestat(TM)
Arecor's Arestat(TM) technology enables superior product
profiles across a broad range of therapies, including various types
of biopharmaceuticals and specialty hospital products. In addition
to its internal portfolio of superior proprietary products in
diabetes and other indications, Arecor leverages the Arestat(TM)
technology in partnerships with leading pharmaceutical and
biotechnology companies to deliver enhanced formulations of their
therapeutic products under a technology licensing model .
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCNKPBNCBKDQBD
(END) Dow Jones Newswires
February 16, 2023 02:00 ET (07:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024